Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other financing activities (2024 - 2025)

Historic Other financing activities for NewAmsterdam Pharma (NAMS) over the last 2 years, with Q1 2025 value amounting to $1.6 million.

  • NewAmsterdam Pharma's Other financing activities rose 20796.12% to $1.6 million in Q1 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $515000.0 for FY2024, which is N/A changed from last year.
  • As of Q1 2025, NewAmsterdam Pharma's Other financing activities stood at $1.6 million, which was up 20796.12% from $515000.0 recorded in Q1 2024.
  • Over the past 5 years, NewAmsterdam Pharma's Other financing activities peaked at $1.6 million during Q1 2025, and registered a low of $515000.0 during Q1 2024.